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Impaired wound healing is a severe clinical challenge and research into finding effective
wound healing strategies is underway as there is no ideal treatment. Gelatinous material
from the umbilical cord called Wharton’s jelly is a valuable source of mesenchymal stem
cells which have been shown to aid wound healing. While the cellular component of
Wharton’s jelly has been the subject of extensive research during the last few years, little
is known about the de-cellularized jelly material of the umbilical cord. This is important
as they are native niche of stem cells. We have isolated Wharton’s jelly from umbilical
cords and then fractionated acellular gelatinous Wharton’s jelly (AGWJ). Here, we show
for the first time that AGWJ enhances wound healing in vitro as well as in vivo for
wounds in a murine model. In vivo staining of the wounds revealed a smaller wound
length in the AGWJ treated wounds in comparison to control treatment by enhancing
cell migration and differentiation. AGWJ significantly enhanced fibroblast cell migration
in vitro. Aside from cell migration, AGWJ changed the cell morphology of fibroblasts to a
more elongated phenotype, characteristic of myofibroblasts, confirmed by upregulation
of alpha smooth muscle actin using immunoblotting. AGWJ treatment of wounds led to
accelerated differentiation of cells into myofibroblasts, shortening the proliferation phase
of wound healing. This data provides support for a novel wound healing remedy using
AGWJ. AGWJ being native biological, cost effective and abundantly available globally,
makes it a highly promising treatment option for wound dressing and skin regeneration.
Keywords: skin, wound healing, deficient healing, umbilical cord, Wharton’s jelly, stem cell, regenerativemedicine,
tissue regeneration
INTRODUCTION
A wound is described as a disruption of the normal healthy anatomical structure and functional
integrity of the skin (Atiyeh et al., 2002). The wound healing process involves four integrated and
overlapping phases: hemostasis, inflammation, proliferation and tissue remodeling or resolution
(Gosain and DiPietro, 2004). These steps allow for the reformation and revascularization
of the skin by allowing a functional dermis and epidermis to form. About 1.5 billion
people suffer from skin diseases as a consequence of both progressive aging and the lack of
adequate health-care (Valacchi et al., 2012). Among these, skin lesions are highly prevalent
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and can be divided into acute or chronic wounds (Whitney,
2005). It has been reported that acute wounds generally follow
trauma or inflammation and usually heal within 6 weeks
(Valacchi et al., 2012). In certain circumstances, chronic wounds,
also known as non-healing wounds result which do not progress
through the normal wound healing steps and fail to heal within
6 weeks, this type of wound results in an open laceration of
varying degrees of severity (Branski et al., 2009). Such wounds
often enter a state of pathologic inflammation due to a postponed,
incomplete, or uncoordinated healing process. The management
of a chronic wound defined as a barrier defect that has not
healed in 3 months—has become a major therapeutic challenge
throughout the western world, and it is a problem that will only
worsen since the incidence of conditions that prevent wound
healing, such as diabetes, obesity, vascular disorders are on the
rise in addition to burn injuries (Nunan et al., 2014).
The primary goals in the treatment of wounds are rapid
wound closure and a functional and esthetically satisfactory scar.
In order to do so, wound coverage is one of the cornerstones
of wound management (Singer and Clark, 1999). Clinicians
may use various materials and techniques, such as antibiotic
therapy, surgical debridement, negative pressure devices, wound
dressings, hyperbaric oxygen therapy, antimicrobial therapy,
bioengineered skin equivalents and growth factors but these
have limited success which illustrates the complexities of wound
healing. Skin grafts from allogeneic or autologous sources,
reconstructive tissue flaps, and engineered skin substitutes can
also be useful in the treatment of more extensive or chronic
wounds (Valacchi et al., 2012). Although research continues and
skin substitutes gain in efficacy, wound healing remains a clinical
challenge, particularly with an aging population (Jeschke et al.,
2015, 2016). Clinical and pre-clinical studies using cell-based
therapies are being gradually introduced into medical care to
manage skin wounds because they can repair/replace damaged
tissue with a healthy tissue due to their natural ability to produce
cytokines and molecules necessary for wound healing (Marfia
et al., 2015; Markeson et al., 2015; Nicholas et al., 2016a,b).
In 1991 McElreavey et al. first isolated the mesenchymal
stromal cells from the Wharton’s jelly portion of the umbilical
cord (McElreavey et al., 1991). Wharton’s Jelly is a source
of perinatal mesenchymal stem cells (WJ-MSC) with unique
properties of both embryonic and adult stem cells (Pirjali et al.,
2013). Wharton’s jelly-derived MSCs have the ability to maintain
phenotypic attributes, cell growth kinetics, cell cycle pattern,
in vitro multilineage differentiation plasticity, apoptotic pattern,
normal karyotype-like intrinsic MSC properties in long-term
in vitro cultures (Sabapathy et al., 2014). Several studies have
investigated cellular therapy with WJ-MSCs, alone or within a
scaffold (Azari et al., 2011; Shohara et al., 2012; Fong et al.,
2014; Ribeiro et al., 2014; Sabapathy et al., 2014). Studies have
elucidated the role of WJ-MSCs for various applications, such
as for neurological disorders (Shalitin et al., 2003), kidney injury
(Du et al., 2013), lung injury (Moodley et al., 2009), liver injury
and cancer therapy (Sabapathy et al., 2014). We have recently
reported that WJ-MSCs conditioned-medium with its secretome
has positive effects on wound healing in vitro (Arno et al.,
2014).
Mesenchymal stem cells in Wharton’s jelly are in close
interaction with their extra cellular matrix. Considering that
the secretome of WJ-MSCs enhances wound healing in vitro,
we asked whether the native extracellular matrix of these cells,
which is not necessarily secreted by WJ-MSCs, have any effect
on skin healing. The Wharton’s jelly itself without cells has not
been investigated with regards to wound healing. Wharton’s jelly
contains a significant amount of extracellular matrix components
which are composed primarily of collagen, hyaluronic acid,
and various sulphated proteoglycans. It is well-known that
biosynthesis of extracellular matrix components is enhanced by
several peptide growth factors, mainly insulin-like growth factor
(IGF) (Edmondson et al., 2003), fibroblast growth factor (FGF)
(Yu et al., 2003) and transforming growth factor b (TGF-b)
(Shalitin et al., 2003). These growth factors may accumulate
within Wharton’s jelly to support the cells (e.g., MSCs). We,
therefore, hypothesized that acellular gelatinous Wharton’s jelly
(AGWJ) enhances skin wound healing. Here we report on the
effects of AGWJ treatment on fibroblast cells of the dermis
through in vitro experiments. We then performed wound healing
experiments on 8 weeks old male C57/black 6 mice to establish
the effect of AGWJ treatment on wounds in vivo. The resulting




Tissue culture plastic ware were purchased from BD FalconTM
(Bedford, MA, USA), and all tissue culture media and
supplements were purchased fromWisent Inc. (St-Jean-Baptiste,
QC, Canada), unless otherwise stated. Fibroblast cell culture
medium was high-glucose Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and
1% antibiotic–antimycotic solution. Primary human normal skin
fibroblasts were obtained from skin tissue samples. The skin was
dissected to remove any underlying fat from the dermis, cut into
small explant pieces of 2 to 4mm, and cultured in 10 cm dishes.
When fibroblast cells had migrated out of the tissue and onto the
plate, the tissue pieces were removed. When fibroblasts reached
to 70% confluence, approximately within 1 week, they were
trypsinized with 0.05% trypsin in preparation for subculture.
Fibroblasts were subcultured in 75 cm2 tissue culture flasks at a
density of 5000 cells/cm2.
Acellularization of Wharton’s Jelly
Sterile umbilical cords were obtained from cesarean sections
performed by surgeons from the department of Gynecology and
Obstetrics at Sunnybrook Health Sciences Center after obtaining
consent from the patients. The cords which were on average
20 cm in length were cut in half. The 10 cm half cords were
then cut open lengthwise to reveal the Wharton’s jelly contents.
The cord pieces were then washed by dipping them in a 2%
antibiotic/antimycotic PBS solution followed by dipping them
in a 1% antibiotic/antimycotic PBS solution. The cord was then
opened completely and a sterile scalpel was used to scrape the
jelly out of the umbilical cord. The jelly (approximately 5ml)
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was then placed in a 50ml conical tube with 20ml of 1×
DMEM complete media and resuspended vigorously using a
5ml pipette to break apart the jelly. The resuspended jelly in
media was then centrifuged at 1400 rpm for 10min. The cells
and cord debris were pelleted. The supernatant with AGWJ was
collected and frozen at −80◦C. The cell pellet was discarded
(Supplemental Figure 1).
Cell Migration Study: Scratch Assay
Normal human skin fibroblasts were seeded in six well plates at
a cell density of 20,000 cells/well. When the wells had reached
to 100% cell confluency, two scratches were made with a 1000
µl pipette tip. The media was then aspirated and the cells
were washed with PBS. The PBS was aspirated. One well was
immediately stained with crystal violet as a 0 h time point.
Treatment media of AGWJ in DMEM or complete DMEM
control media was added to the cells. After 24 h, the cells were
stained with crystal violet. Images were taken on a microscope
(Zeiss) with 4× magnification. Eight images were taken per
scratch. Quantification was performed using ImageJ software
(National Institutes of Health, Bethesda, MD, USA). The cells
within the scratch area were counted as the cells in scratch zone.
In VivoWound Healing Model
Eight C57/black 6 (8 weeks old, male, body weight 25 to 30 g)
were obtained from Jackson Laboratory under the guidelines
of the Sunnybrook Research Institute and Sunnybrook Health
Sciences Animal Policy andWelfare Committee of the University
of Toronto. Animal procedures were reviewed and approved
by Sunnybrook Research Institute and Sunnybrook Health
Sciences Centre at University of Toronto animal care and
use committee. Animals were anesthetized and back cutaneous
hair was removed by electrical shaving under anesthesia as
stated in the Animal Protocol. 4 wounds of 6mm diameter
full-thickness skin wounds were created on each side of the
midline. The animals were randomly divided into two groups:
treatment (AGWJ and Matrigel; Corning Matrigel matrix high
concentration product#354262 Corning, NY, USA) and control
(complete DMEM medium and Matrigel). For the 5 day time
point study: 3 mice received control treatment on their wounds
and 3 mice received AGWJ treatment. For the 7 day time point
study: 6 mice received control treatment and 7 mice received
AGWJ treatment. Each wound topically received 100 µl AGWJ
treatment or control DMEM in Matrigel mix. The day of the
wounding was counted as day 0. For the 7 day time point study,
on days 2 and 4 the wounds were redressed. On day 6, 24 h
before sacking the mice, the animals received an intraperitoneal
injection of bromodeoxyuridine (BrdU) (Calbiochem, SanDiego,
CA, USA). For the 5 day time point, the wounds were redressed
on day 2, BrdU injected on day 4 and the mice were sacrificed on
day 5.
Ethical Regulations for Animal Study
The animal experiments were reviewed and approved by, and
performed in accordance with the guidelines and regulations
set forth by the Sunnybrook Research Institute and Sunnybrook
Health Sciences Animal Policy and Welfare Committee of
the University of Toronto, Ontario Canada. All procedures
using animals were approved by the Sunnybrook animal care
committee, approval #15-503(M-1) issued Nov 20, 2015 under
the auspices of Canadian Council on Animal care.
Human umbilical cords were obtained from cesarean sections
performed by surgeons from the Department of Gynecology and
Obstetrics at Sunnybrook Health Sciences Center, University of
Toronto, Toronto, Ontario, Canada. All subjects gave written
informed consent in accordance with the Declaration of Helsinki
Principles. The protocol was approved by Toronto Academic
Health Sciences Network (TAHSN) and University of Toronto-
affiliated Sunnybrook Research Institute and Sunnybrook Health
Sciences Centre Institutional Ethics Review Board approval (REB
number: 017-2011 valid until March 1, 2017), and after getting
patient signed informed consent.
Wound Analysis
On day 5 and day 7 the mice were sacrificed. The wounds were
then excised using a scalpel and surgical scissors. 3 out of the
4 wounds were placed in histology cassettes and fixed in 10%
buffered formalin for 24 h at 4◦ and then switched to a 70%
ethanol solution and then embedded in paraffin. Specimens were
cut into 5 µm sections. Tissue specimens were cut through the
center ormidline of the wound, providing a cross section through
the wound center. Both halves of the wound were then placed
on slides for analysis. The wounds also included some normal
intact skin on either side of the wound. The 4th woundwas frozen
immediately after excision for future analysis purposes. For high
power field (HPF) analysis of wounds, granulation tissue was
selected from the center of the wound which was the healed area
from both the control and AGWJ treated wounds.
Trichrome Stain
Trichrome reagents were from EMS (Hatfield, PA, USA)
unless otherwise stated. Paraffin-embedded slides were heated
for 30 min at 60◦C. Slides were then deparaffinized with
citrosol, followed by rehydration through 100% × 2, 95%, 70%
and washed in distilled water. Slides were placed in Bouin’s
solution (26367–01; EMS, Hatfield, PA, USA) overnight at room
temperature overnight and rinsed under running tap water for
10 min. Hematoxylin stain (HHS16; Sigma, Saint Louis, MO,
USA) and Biebrich scarlet-acid fuchsin solution were applied
sequentially for 10min. Washes were performed after each stain
addition. Slides were differentiated in phosphomolybdic–tungstic
acid for 15 min, and were transferred to aniline blue for 5 min.
Slides were next rinsed and differentiated in 1% acetic acid for
2min then washed in distilled water. Slides were then dehydrated
through 95% ethanol and absolute ethanol followed by clearing
in citrosol. Slides weremounted with SHUR/Mount xylene-based
liquid mounting media (Triangle Biomedical Sciences, Durham,
NC, USA). Images were acquired using a Zeiss Axiovert 200
light microscope at 5×, 10×, 20×, and 40× magnification.
Quantification was carried out using merged images to measure
the entire wound length.
Immunohistochemistry
Paraffin-embedded skin tissue slides were deparaffinized by
heating for 30min at 60◦. Slides were then placed in citrosol (2×),
100% Ethanol (2×), 95% ethanol, 70% ethanol for 3 min each,
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followed by water. Antigen retrieval was then performed using
antigen decloaker (1×; Biocare Medical, Concord, CA, USA)
which was added to the slides in a preheated decloaking chamber
for 4min at 110◦C. For BrdU staining, samples were denatured
with 1.5N HCl for 30 min at 37◦C and neutralized with 0.1M
borate buffered twice for 5min. Samples were blocked with 3%
H2O2 for 10 min, and then washed with washing buffer (0.05M
Tris–HCl, 0.15M NaCl, 0.05% Tween 20 in deionized water).
The primary antibody (mouse monoclonal anti-BrdU, 1:200; Cell
Signaling, Beverly, MA, USA) was diluted in PBS and incubated
at room temperature for 1 h. For α smooth muscle actin (α
SMA) analysis, a different section was probed with αSMA (mouse
monoclonal anti-αSMA, 1:200; clone 1A4; ebioscience, Sandiego
CA, USA) primary antibody diluted in PBS was incubated at
room temperature for 1 h. Slides were then incubated for 15
min with MACH3 mouse probe (Biocare Medical), followed by
MACH3 rabbit or mouse horseradish peroxidase polymer, with
washes in between. The betazoid diaminobenzidine chromogen
kit (Biocare Medical) was mixed and added for 5min or
until brown stain was noticeable. The reaction was terminated
with running water. Nuclear staining was carried out with
hematoxylin for 30 s, followed by differentiation with three dips
in 1.5% acid alcohol and bluing in 0.1% sodium bicarbonate
for 10 s. Sections were dehydrated through 95% and absolute
ethanol to citrosol and mounted with SHUR/Mount. Images
were acquired using a Zeiss Axiovert 200 light microscope at
10× magnification to image the whole section followed by 40×
magnification to further focus on the wound margins and the
wound center. The 40×magnification images were quantified by
positive cells using ImageJ software, and then normalized to the
number of total cells in the 40× field.
Immunofluorescence
Cells were washed with phosphate-buffered saline (PBS) and
fixed for 15 min in 4% paraformaldehyde (Alfa Aesar, Karlsruhe,
Germany). Fixed cells were washed in PBS and permeabilized
for 10 min with 0.5% Triton X-100 solution in PBS. Cells were
washed again and then blocked for 30 min with 1% bovine serum
albumin in 0.5% Triton X-100 in PBS. A mouse monoclonal
αSMA (anti-αSMA, 1:200; clone 1A4; ebioscience, Sandiego CA,
USA) primary antibody was added and incubated overnight at
4◦C. After washing with PBS, the secondary antibody was added
in 1% bovine serum albumin in 0.5% Triton X-100 in PBS
and incubated for 1 h at room temperature in the dark (Alexa
Fluor 488 donkey anti-mouse, 1:500; Life Technologies, Eugene,
OR, USA). The cells were then washed three times with PBS,
the slides were mounted with Vectashield mounting medium
with 4′,6-diamidino-2-phenylindole (DAPI; Vector Laboratories,
Burlingame, CA, USA). Cells were examined and photographed
using an Apotome Axiovert fluorescent imaging system at 10×
magnification (Zeiss, Oberkochen, Germany). Four images were
taken per well and two wells were imaged, one well was AGWJ
treated cells and one was control treated cells.
Cell Viability Assay
Cell viability was performed using the CellTiter-glo luminescent
cell viability assay kit (G7571 Promega, Madison, WI, USA).
Briefly, cells were seeded into a 96 well plate and allowed to grow
for 24 h at 37◦C in a 5% CO2 incubator. After 24 h, the media was
aspirated and AGWJ treatment or control media was added to
the cells. The plate was again incubated for 24 h in the incubator.
After the 24 incubation with treatment, the cell titer glo substrate
was added to the buffer and then added to the plate. The cell
titer glo solution was added in a 1:1 ratio to the volume of media
in the wells. The plate was shaken to mix the solution with the
media and then incubated for 10min at room temperature. After
which the luminescence was read using the Synergy H4 hybrid
multi-mode microplate reader (100 Tigan Street Winooski, VT,
USA).
Cell Lysate Preparation
Cell lysates were prepared on ice. Media was aspirated from
the cells. The cells were washed with PBS, the PBS was then
aspirated. Next, lysis Buffer (RIPA) with 5 mM EDTA, 1×
protease inhibitor, and phosphatase inhibitor was added to the
cells. 150 ul of lysis buffer was added to a 10 cm plate of cells. The
cells were scraped off the plate with a cell scraper. The solution
was placed in an eppendorf tube and incubated on ice for 30min
with vortexing every 10min. The cell lysate was then centrifuged
at 4◦C for 30min at 20,000× g. The supernatant was collected in
an eppendorf tube and stored at−80◦C.
Western Blot Analysis
Briefly, cell lysates (15 µg of protein per well) were separated
by 10% SDS-PAGE gel, proteins were then transferred to
nitrocellulose membrane, after which the blots were blocked
with 5% skim milk in TBST buffer. The blots were washed
three times in TBST buffer and then blots were probed using
the mouse monoclonal αSMA (anti-αSMA, 1:1000; clone 1A4;
ebioscience, Sandiego CA, USA), mouse monoclonal vimentin
(anti-vimentin, 1:1000; Thermofisher Scientific, Waltham MA,
USA). Loading control used was GAPDH (anti-GAPDH, 1:5000,
Cell Signaling, Danvers MA, USA). Primary antibody incubated
overnight at 4◦C. Band intensities were detected, normalized
and quantified with the Chemidoc and Image Lab 5.0 software
(Bio-Rad Laboratories).
Statistical Analysis
The statistical comparisons between the AGWJ treatment and
control groups were performed using a 2-tailed Student’s t-test
for analysis. A P value of <0.05 was considered statistically
significant. Data were graphically represented as the mean of the
target group ± the 95% confidence interval. Microsoft excel was
used for data analysis.
RESULTS
AGWJ Treatment Enhances Wound Healing
in Mice
To validate if there are any beneficial effects of AGWJ on
promoting wound healing in vivo, we performed two wound
healing studies on a murine model. We conducted a 5 day and
a 7 day time point study. Wound length and hence wound
closure were analyzed using trichome staining on excised wounds
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after the end of both studies. The results showed that after 5
days, compared with the control treatment (Figure 1A), AGWJ
treatment led to a significant reduction in the wound size
(Figure 1B). Wound length was measured from the border of
the intact skin on the right side through the wound bed to the
intact skin on the left side of the wound. All of the wounds were
measured and the average wound length for the control treated
wounds was 4184.09 um ± 358.18 and for the AGWJ treated
wounds, the average wound length was 2673.53 um ± 379.02.
∗P < 0.05 (Figure 1C). For the 7 day treatment time point, the
results also display a dramatic reduction in the wound length
with AGWJ treatment as compared with controls, however, the
data does not show significance (Figures 1D–F). These results
show that AGWJ treatment promotes enhanced wound healing
observed through shorter wound length and hence faster wound
closure at the proliferation phase of skin healing in young
mice.
FIGURE 1 | Effect of AGWJ treatment on wound healing in vivo after 5
days and 7 days. Wound length was assessed using trichrome staining. (A)
The representative image displaying the length of a control wound after the 5
day wound healing study. (B) A representative AGWJ treated wound
displaying the healing at the end of the 5 days. (C) Quantitative analysis of the
trichrome stain results comparing the wound length between control and
AGWJ treated wounds. (D) The representative image displaying the length of a
control wound after the 7 day wound healing study. (E) A representative AGWJ
treated wound displaying the healing at the end of the 7 days. (F) Quantitative
analysis of the trichrome stain results comparing the wound length between
control and AGWJ treated wounds. Data shown are mean ± 95% confidence
interval. P<0.05 compared with control. N = 3 for AGWJ and N = 3 for
control treated mice for the 5 day study. N = 6 for control mice for 7 day study,
N = 3 for treatment mice, each N represents one animal. Black arrow head
shows the border of the wound and intact skin. *Indicates the significance of
p < 0.05 compared to control.
AGWJ Treatment Does Not Affect Cell
Proliferation or Cell Viability of Fibroblasts
In an effort to establish the mechanism behind improved
wound healing observed in the mice after the treatment
of wounds with AGWJ, we aimed to determine if AGWJ
treatment affected cell proliferation within the wound. To
investigate this, we quantified the total number of cells in
the center of the wound bed in high power field (20×
magnification). The results did not show a significant difference
in cell count between control treated (Supplemental Figure 2A)
and AGWJ treated wounds (Supplemental Figure 2B) for
the 5 day (Supplemental Figure 2C) time point. For the
7 day time point, the results observed for control treated
wounds (Supplemental Figure 2D) and AGWJ treated wounds
(Supplemental Figure 2E) also did not show a significant
difference (Supplemental Figure 2F) suggesting that AGWJ
does not affect cellularity of wounds. Several factors affect
cellularity of the tissues including the rate of proliferation.
We first measured cell viability in vitro in human fibroblasts
by exposing the cells to AGWJ and the control media. The
results did not show a significant difference in viability between
AGWJ and control treated cells (Supplemental Figure 3). In
order to verify the proliferation state of cells in granulation
tissue in vivo, we also analyzed BrdU expression through
IHC analysis. Positive BrdU protein expression was quantified
as a brown stain in the nucleus of fibroblasts in the
wound bed at the 5 and 7 day time points. Although
the number of BrdU positive cells in the AGWJ treated
group (Figure 2B) was slightly lower than the control group
(Figure 2A) at 5 days post wounding (Figure 2C) and was higher
than the control in 7 days post wounding (Figure 2F), the
difference in results between AGWJ (Figures 2B,E) and controls
(Figures 2A,D) were not significant. Therefore, collectively
our results suggest that AGWJ does not enhance wound
healing through modulation of cell proliferation in the
wound bed.
Unlike Proliferation, AGWJ Enhances
Fibroblast Migration
Since our in vivo wound analysis demonstrated that enhanced
wound healing post AGWJ treatment was not due to cell
proliferation in the wound bed, we investigated the possibility of
enhanced cell migration causing faster wound closure. Cellular
migration is an essential step during skin healing (Amini-Nik
et al., 2011, 2014). To test the effect of AGWJ treatment on
cell movement in wound healing, cell migration was analyzed
in vitro by performing a scratch assay. Human fibroblasts were
used as they are the main cellular component of the dermis.
Two horizontal scratches were made in a confluent well of
fibroblasts and either control media or AGWJ treatment was
added. Images were taken at t = 0 h and t = 24 h (Figure 3A).
After 24 h we quantified cell infiltration within the scratch zone
and observed a significantly higher number of cells in the
scratch zone for the AGWJ treated scratches as compared to
the controls. For the control treated cells, an average of 58.85 ±
22.95 fibroblasts had migrated into the scratch zone, for AGWJ
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FIGURE 2 | BrdU analysis of cell proliferation in the wound bed after AGWJ treatment compared to controls. (A) Representative IHC image displaying
BrdU-positive cells in the wound bed of a control treated wound after 5 day time point. (B) BrdU-positive cells in an AGWJ treated wound after 5 day time point. (C)
Quantification of BrdU-positive cells in the wound bed after AGWJ treatment for 5 day time point compared with control treatment. The graph shows the percentage
of BrdU positive cells per high power field (40×). (D) Representative IHC image displaying BrdU-positive cells in the wound bed of a control treated wound after 7 day
time point. (E) BrdU-positive cells in an AGWJ treated wound after 7 day time point. (F) Quantification of BrdU-positive cells in the wound bed after AGWJ treatment
for 7 days compared with control treatment. The graph shows the percentage of BrdU positive cells per high power field (40×). Data shown are mean ± 95%
confidence interval. For the 7 day study, N = 7 for AGWJ treated mice and N = 6 for control mice. For the 5 day study, N = 3 for AGWJ and N = 3 for control treated
mice. Each N represents one animal. Black arrows point to BrdU positive brown stained nuclei and arrow heads point to BrdU negative blue nuclei.
an average of 117.33 ± 22.86 cells migrated into the scratch
(n = 3 control and n = 3 AGWJ, ∗∗p < 0.01) (Figure 3B).
Therefore, as shown in Figure 3A, the AGWJ treated fibroblast
cells had started to close the wound after 24 h whereas the control
cells had minimal migration into the scratch zone. Thus, AGWJ
treatment of fibroblasts promotes their migration ability. We also
observed that the AGWJ treatment altered cell morphology for
fibroblasts. After 24 h the fibroblasts appeared to attain a more
elongated phenotype as compared to the control media treated
cells.
AGWJ Treatment Promotes
Myofibroblastic Phenotype In Vitro
Since we detected a smaller wound size in the AGWJ treated
wounds in vivo and our in vitro results demonstrated enhanced
cell migration after AGWJ treatment, our findings support the
notion that AGWJ augments cell migration. And that improved
cell migration is the underlying mechanism for faster wound
healing. Moreover, as mentioned, we observed a change in
the phenotype of the cells treated with AGWJ in vitro and
a smaller wound size in vivo, both of which suggest a pro
myo-fibroblastic phenotype due to AGWJ treatment occurring
earlier which led to faster contraction which is characteristic of
enhanced wound healing. To evaluate this in vitro, we treated
fibroblasts with AGWJ or control media and observed through
immunofluorescence analysis that αSMA protein is increased
dramatically in fibroblasts after AGWJ treatment (Figure 4B)
as compared with control treated cells (Figure 4A). This result
was corroborated by western blot analysis which detected a
dramatically higher level of αSMA protein expression in AGWJ
treated fibroblasts for two different human fibroblast samples
(Figure 4C). The western blot band densitometry for αSMA was
normalized to GAPDH and the quantification shows an almost
8-fold increase in αSMA protein levels after AGWJ treatment as
compared with control DMEMmedia (Figure 4D). Furthermore,
normal human fibroblasts display high levels of vimentin, which
is reduced after AGWJ treatment for 24 h, observed in two
different human fibroblast samples through western blot analysis
(Supplemental Figure 4).
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FIGURE 3 | Analysis of cell migration in vitro for fibroblasts. (A) The top
panel shows representative images of a control treated scratch at time point
0 h compared with the control treated scratch after 24 h. The lower panel
displays the fibroblast scratch assay with AGWJ treatment at time point 0 h
and then the scratch zone is imaged after incubation with AGWJ for 24 h. (B)
The graph shows the average number of fibroblast cells that have infiltrated
the scratch zone after 24 h for control media treated cells compared to AGWJ
treated cells. **Indicates the significance of p < 0.01 compared to control.
FIGURE 4 | AGWJ treatment promotes myofibroblastic phenotype in
vitro detected through αSMA expression. (A) Immunofluorescence image
of control media treated fibroblasts compared with (B) AGWJ treated
fibroblasts after 24 h of treatment. DAPI blue fluorescence represents nucleus
and rhodamine red represents αSMA. (C) Western blot analysis of two normal
human fibroblast cells (Hu-Fibro) treated with either control DMEM media or
AGWJ treatment for 24 h in order to analyze αSMA protein expression.
Loading control was GAPDH protein. (D) Densitometry analysis of the western
blot. αSMA protein expression was normalized to GAPDH.
AGWJ Augments the Differentiation of
Fibroblasts to Myofibroblasts in the
Wound Bed
Because we detected an elevated level of αSMA in fibroblasts
in vitro, which is a characteristic of myofibroblasts we
FIGURE 5 | Effect of AGWJ treatment on αSMA expression in the
wound bed in vivo. (A) αSMA expression in the granulation tissue of control
treated wounds after 5 days. (B) αSMA expression in the granulation tissue of
AGWJ treated wounds after 5 days. (C) αSMA expression in the granulation
tissue of control treated wounds after 7 days. (D) αSMA expression in the
granulation tissue of AGWJ treated wounds after 7 days.
wanted to investigate if this result is translated in vivo.
Immunohistochemistry analysis of αSMA in wounds excised
from the day 5 and day 7 time points demonstrate that for the 5
day time point; the AGWJ treated wounds express higher levels of
αSMA (Figure 5B) whereas the control wounds express very little
to no αSMA (Figure 5A). Surprisingly, in contrast, for the 7 day
time point, we detected that the wound beds for both the AGWJ
treatment (Figure 5D) and the control treatment (Figure 5C)
both expressed high levels of αSMA.Hence, it appears that AGWJ
accelerates the wound healing process through earlier fibroblast
differentiation into myofibroblasts as seen at day 5, and therefore
shortens the proliferation phase of skin wound healing.
DISCUSSION
There is a substantial amount of literature which investigate
the beneficial effects of cellular therapy with WJ-MSCs, alone
or within a scaffold (Zebardast et al., 2010; Azari et al., 2011;
Shohara et al., 2012; Arno et al., 2014; Fong et al., 2014;
Ribeiro et al., 2014; Sabapathy et al., 2014). Emerging reports
are showing the promising role of decellularized biological
matrices for tissue repair (Boccafoschi et al., 2015). Our group
has reported that WJ-MSCs conditioned-medium has positive
effects on wound healing in human in vivo in full-thickness
skin excisional wounds on a mouse model through paracrine
signaling via several mechanisms: upregulation of wound healing
factors’ gene expression, such as TGF-ß2, HIF-1α and PAI-1 in
addition to enhancing human skin fibroblasts proliferation and
migration (Arno et al., 2014). It is known that the niche or
microenvironment of stem cells is crucial in supporting theMSCs
and that there is significant cross talk and signaling that occurs
between the cells and the environment (Boccafoschi et al., 2015;
Khodadi et al., 2016). Moreover, there is the secretome of stem
cells which is within the Wharton’s jelly. In addition to being a
reservoir of MSCs,Wharton’s Jelly has been reported to be a great
source of pro-angiogenic and wound healing promoting factors,
such as IGF-1, TGF-ß1, VEGF, PDGF, EGF, bFGF, HGF, IL-6, and
IL-8 (Sobolewski et al., 2005; Liu et al., 2012; Arno et al., 2014;
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Biazar, 2014; Edwards et al., 2014). These factors are also believed
to stimulate the cells within Wharton’s Jelly to produce large
amounts of ECM components (Sobolewski et al., 2005). Because
AGWJ is present in the native niche of MSCs and supports
these stem cells, in addition to being a source of wound healing
factors, we hypothesized that AGWJ has beneficial effects on skin
wound healing. We, therefore, isolated the Wharton’s jelly, and
acellularized it (Supplemental Figure 1). In the umbilical cord,
whether AGWJ promotes stem cell behavior and supports these
MSCs in their niche or whether other cell types contribute to the
microenvironment and consequently affects stem cell behavior is
unknown.
The findings from this study established that AGWJ leads to
healing at an earlier time point in a murine model demonstrated
a significant reduction in wound length after AGWJ treatment
as compared to control treatment after 5 days. We chose 5
days and 7 days as our time points for this study because, in
a mouse model, day 5 is considered the peak of proliferation
phase and day 7 is the start of the wound maturation phase
in wound healing (Bielefeld et al., 2013). Despite the positive
effect on wound healing of young animals that we report here,
it is yet to be determined whether this effect can rescue deficient
healing observed in elderly or diabetic patients. More research
is warranted to address their effect on a deficient skin healing
model.
We also tried to understand the mechanism of the
enhanced wound healing through investigating several possible
mechanisms, such as: cell viability, cell proliferation, and cell
migration. We started by investigating cellularity in the wound
by doing a cell count in the granulation tissue at HPF and also
detecting cell proliferation through BrdU staining of the wounds.
The results did not show any significant difference between
AGWJ and controls. Therefore, our in vivo wound analysis
suggests that enhanced wound healing post AGWJ treatment was
not due to an increase in cell number. To further characterize this
observation in vitro, we performed a viability assay using AGWJ
and control media treatment. Cell proliferation can have an effect
on cell viability and hence cellularity. Again, our data showed that
AGWJ does not affect the viability of fibroblasts in vitro. Taken
together, this set of data establishes that AGWJ’s mechanism
of action is not through enhancing proliferation, viability, and
cellularity of cells.
We next investigated the possibility of enhanced cell
migration causing faster wound closure. Cell motility and
migration play critical roles during wound healing (Schneider
et al., 2010; Amini-Nik et al., 2014). Indeed our in vitro results
confirmed that AGWJ causes increased fibroblast migration.
Moreover, we observed a change in the phenotype of the
fibroblast cells treated with AGWJ and a smaller wound size in
vivo, both of which suggest a pro myo-fibroblastic phenotype.
IHC analysis of the wounds for αSMA showed an enhanced
expression of αSMA in the granulation tissue after 5 days in
comparison to control treated wounds. Surprisingly at the 7
day time point the αSMA expression in control and AGWJ
treated wounds seems to be even. This suggests that AGWJ
accelerates the proliferation phase of wound healing by causing
a faster differentiation of fibroblasts to myofibroblasts confirmed
through αSMA expression. The control wounds follow their
normal course of differentiation and catch up later at 7 days post
wounding. This result was supported by our in vitro analysis
of fibroblasts post AGWJ treatment which showed an elevated
expression of αSMA protein expression compared to controls.
This report shows for the first time that AGWJ enhances
wound healing by accelerating the proliferation phase of skin
healing mainly through enhancing cell migration and wound
closure. Several diseases, including wounds in diabetic patients
of elderly patients, are associated with delayed wound healing and
AGWJmight be a remedy for this group of patients. Although we
have found a mechanism through TGF-beta signaling pathway
for the positive effect of AGWJ on skin healing, it is yet
to be verified whether other factors that might contribute to
this observation. Future research should focus on the further
characterization of AGWJ and to find the active ingredients,
particularly for the components of signaling pathways which
have essential roles during skin healing, such as Wnt/β-catenin
as well as TGF-β/Smad 2 signaling pathways (Amini Nik et al.,
2007; Poon et al., 2009; Bielefeld et al., 2011). Since the AGWJ
enhances wound healing mainly through cell migration and not
cell proliferation, it might be an ideal remedy for the deficient
skin healings which are associated with deficient migration. We
have recently reported that elderly burn patients have reduced
stem cell pool, a deficient migration of MSC and an altered
activation of crucial signaling pathways for skin healing (Jeschke
et al., 2015). Therefore, since our data suggests that AGWJ
enhances cell migration, causes an earlier differentiation of
fibroblasts to myofibroblasts and hence allows for earlier wound
contraction, this treatment can have significant wound healing
benefits, particularly for this group of patients.
Economy of AGWJ
The findings from this study demonstrate the discovery of AGWJ
which is the very native and niche material of stem cells within
umbilical cords for the purpose of skin wound healing.We collect
approximately 5ml of jelly from each umbilical cord. To this
5ml of jelly, we added 15ml of DMEM complete media and re-
suspended the jelly so that we had a total of 20ml solution. For
our in vivo study on mice, we placed 50 ul of AGWJ solution
mixed with 50 ul of matrigel (1:1) on each wound, covering and
enhancing 0.3 cm2 area of the wound in the animal. Collectively
each umbilical cord provides AGWJ material for approximately
115 cm2 area of the wound (Supplemental Figure 5). Unlike
the secretome of MSCs which needs an equipped facility to
isolate, isolation of AGWJ needs minimal equipment and can be
performed in any facility in developing countries.
In conclusion, we demonstrate for the first time that AGWJ
enhances wound healing and establish a mechanism for its role as
a potential therapeutic modality for deficient skin wound healing.
Because each umbilical cord provides approximately enough
AGWJ to cover 115 cm2 area of a wound, is easy to isolate and it is
available globally; umbilical cord AGWJ has far reaching benefits
for wound healing not just in the developed world but also
in developing countries where affordable and available wound
healing remedies are of critical need.
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Supplemental Figure 1 | Decellularization of Wharton’s Jelly. The degree of
decellularization of Wharton’s jelly was assessed using DAPI immunofluorescence
staining nuclei. Panel one shows complete WJ before decellularization with many
cells, panel two shows AGWJ without any cells.
Supplemental Figure 2 | Effect of AGWJ treatment on cellularity in the
wound bed. (A) Trichome stain analysis used to quantify the cell number in the
wound center. (A) Representative image showing cellularity in the wound bed after
5 days of control treatment. (B) Image showing cellularity in wound bed post
AGWJ treatment after 5 day time point. (C) Quantification of average cell number
within the wound bed comparing control treated wounds with AGWJ treated
wounds after 5 days. (D) The representative image displaying cellularity in the
wound bed after 7 days of control treatment. (E) Image showing cellularity in
wound bed post AGWJ treatment for 7 day time point. (F) Quantification of
average cell number within the wound bed comparing control treated wounds
with AGWJ treated wounds post 7 day treatment. The graph shows the average
cell number in the wound bed of control compared to AGWJ treated mice under
20× magnification. Data shown are mean ± 95% confidence interval. For the 7
day study N = 7 for AGWJ treated mice and N = 6 for control mice, each n
represents one animal. For the 5 day study, N = 3 for AGWJ and N = 3 for control
treated mice.
Supplemental Figure 3 | AGWJ does not affect fibroblast viability in vitro.
Quantitative analysis of cell viability post control and AGWJ treatment for 24 h.
Luminescence was read using the Synergy H4 hybrid multi-mode microplate
reader.
Supplemental Figure 4 | AGWJ treatment reduces vimentin expression in
fibroblasts. Western blot analysis of two normal human fibroblast cells (Hu-Fibro)
treated with either control DMEM media or AGWJ treatment for 24 h. Loading
control was GAPDH protein.
Supplemental Figure 5 | Schematic illustrating the isolation procedure for
AGWJ and the subsequent economical use of AGWJ as a remedy for
wound healing.
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